Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Accounts Payables (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 5 years of Accounts Payables data on record, last reported at $101.5 million in Q4 2025.

  • For Q4 2025, Accounts Payables rose 56.71% year-over-year to $101.5 million; the TTM value through Dec 2025 reached $101.5 million, up 56.71%, while the annual FY2025 figure was $101.5 million, 56.71% up from the prior year.
  • Accounts Payables reached $101.5 million in Q4 2025 per TARS's latest filing, up from $76.4 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $101.5 million in Q4 2025 and bottomed at $8.1 million in Q3 2021.
  • Average Accounts Payables over 5 years is $37.8 million, with a median of $16.8 million recorded in 2022.
  • Peak YoY movement for Accounts Payables: increased 14.17% in 2022, then skyrocketed 173.48% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $8.7 million in 2021, then increased by 14.17% to $9.9 million in 2022, then soared by 139.06% to $23.7 million in 2023, then surged by 173.48% to $64.8 million in 2024, then skyrocketed by 56.71% to $101.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $101.5 million in Q4 2025, $76.4 million in Q1 2025, and $64.8 million in Q4 2024.